Patents Assigned to Lipopeptide AB
-
Patent number: 9125875Abstract: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.Type: GrantFiled: December 11, 2014Date of Patent: September 8, 2015Assignee: Lipopeptide ABInventors: Mona Ståhle-Bäckdahl, Johan Heilborn, Anders Carlsson, Conny Bogentoft
-
Patent number: 8936807Abstract: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.Type: GrantFiled: July 9, 2013Date of Patent: January 20, 2015Assignee: Lipopeptide ABInventors: Mona Ståhle-Bäckdahl, Johan Heilborn, Anders Carlsson, Conny Bogentoft
-
Patent number: 8506994Abstract: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.Type: GrantFiled: July 28, 2011Date of Patent: August 13, 2013Assignee: Lipopeptide ABInventors: Mona Ståhle-Bäckdahl, Johan Heilborn, Anders Carlsson, Conny Bogentoft
-
Publication number: 20130108682Abstract: The present invention provides a wound care product comprising a wound care material and a polypeptide having wound care properties. In one embodiment, the wound care material comprises or consists of alginates, amorphous hydrogels, sheet hydrogels, hydrofibres, foams and mixtures thereof. In a further embodiment, the polypeptide having wound care properties is a cathelicidin, such as LL-37. The invention further provides methods of treatment of wounds using the products of the invention.Type: ApplicationFiled: October 19, 2012Publication date: May 2, 2013Applicant: LIPOPEPTIDE ABInventor: LIPOPEPTIDE AB
-
Patent number: 8012933Abstract: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.Type: GrantFiled: September 12, 2008Date of Patent: September 6, 2011Assignee: Lipopeptide ABInventors: Mona Ståhle-Bäckdahl, Johan Heilborn, Anders Carlsson, Conny Bogentoft
-
Publication number: 20100178320Abstract: The present invention provides a wound care product comprising a wound care material and a polypeptide having wound care properties. In one embodiment, the wound care material comprises or consists of alginates, amorphous hydrogels, sheet hydrogels, hydrofibres, foams and mixtures thereof. In a further embodiment, the polypeptide having wound care properties is a cathelicidin, such as LL-37. The invention further provides methods of treatment of wounds using the products of the invention.Type: ApplicationFiled: June 25, 2008Publication date: July 15, 2010Applicant: Lipopeptide ABInventor: Bengt Westrin
-
Patent number: 7741275Abstract: The present invention provides agents for inhibiting the proliferation of cancer cells, wherein the agent inhibits the biological activity of hCAP18/LL-37. In a preferred embodiment, the agent alters the transcription, translation and/or binding properties of hCAP18/LL-37. Preferably, the agent is selected from the group consisting of short interfering RNA (siRNA) molecules, antisense oligonucleotides and compounds with binding affinity for hCAP18/LL-37. The invention further provides methods for inhibiting the proliferation of cancer cells in a patient, as well as methods and kits for diagnosing cancer.Type: GrantFiled: December 16, 2005Date of Patent: June 22, 2010Assignee: Lipopeptide ABInventors: Mona Ståhle, Johan Heilborn, Margareta Frohm Nilsson, Gunter Weber
-
Publication number: 20100056431Abstract: The present invention provides the use of a polypeptide comprising an amino acid sequence according to SEQ ID NO: 1 (corresponding to the N-terminal 25 amino acid fragment of the human antimicrobial protein, LL-37) or a biologically active fragment, variant, fusion or derivative thereof, in the preparation of a medicament for the treatment of cancer. In particular, the inventions provides the use such polypeptides, or a fragment, variant, fusion or derivative thereof, to inhibit the proliferation and/or metastasis of cancer cells, such as breast cancer cells. The invention further comprises methods for the treatment of cancer in a patient.Type: ApplicationFiled: June 20, 2007Publication date: March 4, 2010Applicant: LIPOPEPTIDE ABInventors: Mona Stahle, Gunther Weber
-
Patent number: 7452864Abstract: Use of the antimicrobial cathelicidin peptide ll-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithalial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.Type: GrantFiled: January 28, 2004Date of Patent: November 18, 2008Assignee: Lipopeptide ABInventors: Mona Ståhle-Bäckdahl, Johan Heilborn, Anders Carlsson, Conny Bogentoft
-
Publication number: 20080187530Abstract: The present invention provides agents for inhibiting the proliferation of cancer cells, wherein the agent inhibits the biological activity of hCAP18/LL-37. In a preferred embodiment, the agent alters the transcription, translation and/or binding properties of hCAP18/LL-37. Preferably, the agent is selected from the group consisting of short interfering RNA (siRNA) molecules, antisense oligonucleotides and compounds with binding affinity for hCAP18/LL-37. The invention further provides methods for inhibiting the proliferation of cancer cells in a patient, as well as methods and kits for diagnosing cancer.Type: ApplicationFiled: December 16, 2005Publication date: August 7, 2008Applicant: Lipopeptide ABInventors: Mona Stahle, Johan Heilborn, Margareta Frohm Nilsson, Gunther Weber
-
Publication number: 20080058249Abstract: The invention relates to colloidal aqueous solutions of complexes between a charged peptide and a bilayer-forming galactolipid. The colloidal solutions can be used as a drug delivery system for the charged peptide in the treatment of infections, in wound healing and in other diseases.Type: ApplicationFiled: February 23, 2005Publication date: March 6, 2008Applicant: Lipopeptide ABInventors: Anders Carlsson, Conny Bogentoft, Mona Stahle, Johan Heilborn
-
Publication number: 20080038374Abstract: The present invention relates to the use of a vitamin D compound active in up-regulating the expression and production of hCAP18 in humans for the manufacture of a medicament for treatment of conditions deficient in or benefiting from LL-37. The vitamin D active compound can be used as a medicament for treatment of injured tissues, chronic ulcers, burn wounds, skin infections and atopic dermatitis and for improving the microvasculature. UVB irradiation can also be used to up-regulate hCAP18.Type: ApplicationFiled: July 26, 2005Publication date: February 14, 2008Applicant: Lipopeptide ABInventors: Mona Stahle, Gunther Weber, Johan Heilborn